Skip to content
Home/Companies/Biotech/eFFECTOR Therapeutics
eFFECTOR Therapeutics

eFFECTOR Therapeutics

Biotech·US·Exited 2021·Held 8yr
Entry
2013
Hold
8yr
Exit
2021

Who owns eFFECTOR Therapeutics?

eFFECTOR Therapeutics is an American Biotech company, formerly owned by Abingworth, exited in 2021 (exit via IPO). No current private equity owner is on file.

Hand-verified · updated 2026-05-21

Open JSON · CC-BY
Abingworth
Investor
Abingworth
Abingworth Bioventures VI · 2014 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusAcquired
Websiteeffector.com
Exit Type
IPO
Buyer
Locust Walk Acquisition Corp.
Exit Year
2021

More from Abingworth Bioventures VI

Other portfolio companies in the same fund.

Verona Pharma
Verona Pharma
Exited 2025
BiotechUK
to Merck & Co.
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Active
HealthcareUS· 2022
Exicure
Active
BiotechUS· 2019
Soleno Therapeutics
Soleno Therapeutics
Exited 2026
BiotechUS· 2018
to Neurocrine Biosciences
Tizona Therapeutics
Tizona Therapeutics
Active
BiotechUS· 2016
Median Technologies
Active
MedTechFrance· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns eFFECTOR Therapeutics?

eFFECTOR Therapeutics was formerly owned by Abingworth, exited in 2021. No current private equity owner is on file.

Who did eFFECTOR Therapeutics sell to?

Abingworth sold eFFECTOR Therapeutics to Locust Walk Acquisition in 2021 (IPO).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue